卫信康(603676) - 卫信康投资者关系活动记录表（2024-04-29）

Group 1: Company Overview - The company adheres to the corporate spirit of "Responsibility, Sharing, Credibility, Innovation" and aims to "Care for Life, Maintain Health" as its mission [3] - The company focuses on R&D innovation, combining imitation and innovation, to enhance its technological capabilities and expand into differentiated markets [3] Group 2: Financial Performance - In 2023, the company achieved a revenue of CNY 1.323 billion, a decrease of 5.43% year-on-year; net profit attributable to shareholders was CNY 214 million, an increase of 20.94% [3] - In Q1 2024, the company reported a revenue of CNY 318 million, down 9.29% year-on-year; net profit attributable to shareholders was CNY 94.91 million, up 57.54% [3] Group 3: Dividend Distribution - The company plans to distribute a cash dividend of CNY 2.85 per 10 shares, totaling approximately CNY 124 million (including tax) [3] Group 4: R&D Investment - R&D investment for 2021 was CNY 60 million, up 32% year-on-year; in 2022, it was CNY 80 million [3] - The company has over 40 ongoing R&D projects, with expectations for 6 products to receive approval in 2024 [5] Group 5: Product Development - In 2023, the company obtained drug registration certificates for 3 products and received acceptance for 3 new drug registration applications [5] - In 2024, the company has received acceptance for several product registration applications, including potassium aspartate injection and compound amino acid injection [5]